Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

PEPperPRINT GmbH Introduces Novel Biomarker Set for Rheumatoid Arthritis Diagnosis at the 13th International Congress on Autoimmunity

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

PEPperPRINT GmbH, an innovative and award-winning biotech company and the leading provider of high-density peptide microarrays for antibody and serum analyses, is going to introduce a novel biomarker set for the early diagnosis of rheumatoid arthritis (RA) in a talk at the 13th International Congress on Autoimmunity to be held in Athens, Greece, on June 10-13th this year.

Dr. Kirsten Heiss, head scientist at the Research and Development unit at PEPperPRINT, is scheduled to present on Sunday, June 12, 2022 at 11:40 am CEST (2:40 am PDT / 5:40 am EDT) during the Rheumatoid Arthritis session held at Trianti Hall. The novel biomarker set consists of linear and cyclic peptides, including citrulline and particularly homocitrulline as posttranslational modifications. While today 30-50% of early RA patients are seronegative with available tests, the new biomarker set reaches RA sensitivity of up to 89%. It can be established as a new test for rheumatoid arthritis or combined with existing serological tests.

Dr. Heiss’s presentation entitled “Novel biomarkers for seronegative rheumatoid arthritis” will cover findings and prospects from a study aimed to identify epitope biomarkers from rheumatoid arthritis sera using a combination of serological profiling using high-density peptide microarrays, bead-based diagnostic platforms, and machine learning-based bioinformatic analyses.

“Not all biomarker discovery projects are successful; sometimes you’ll be disappointed at a late stage of the discovery and development pipeline. However, the outcome of our rheumatoid arthritis study looks completely different and has the potential to leverage the early diagnosis of RA very soon. Our biomarker set was validated with more than 1,000 RA and control sera in a bead-based diagnostic format, and is a milestone for PEPperPRINT. We further look forward to apply our technologies and expertise in new biomarker projects in cancer, infectious disease, and autoimmune research” explains Dr. Volker Stadler, CEO of PEPperPRINT.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine